Dextera Surgical Hosts Hands-on Training Course for Video-Assisted Thoracic Surgery Techniques Using MicroCutter 5/80™ for ...
September 27 2017 - 10:30AM
Business Wire
Dextera Surgical Inc. (Nasdaq: DXTR), a company developing and
commercializing the MicroCutter 5/80™ Stapler, today announced that
it sponsored an international hands-on training course for thoracic
surgeons from across Europe focused on advanced techniques for
video-assisted thoracic surgery (VATS).
During this day-long event in Tubingen, Germany, a faculty of
world-leading thoracic surgeons taught advanced techniques which
included the use of the MicroCutter 5/80™ in VATS for anatomical
segmentectomy procedures. A segmentectomy is a procedure that
removes a portion of a lobe of the lungs (typically comprised of
two or more segments) rather than the entire lobe. Segmentectomy
procedures require precision in stapling, as the operating area is
tightly confined and the vessels are difficult to access.
New advances in lung cancer diagnoses are enabling earlier
diagnosis and therefore earlier treatments for patients with lung
cancer. Increasingly, segmentectomy rather than a traditional
lobectomy is considered as a viable treatment for early-stage lung
cancer which preserves more lung tissue than a complete
lobectomy.
“The MicroCutter 5/80 is an ideal tool for VATS lobectomy and
especially for segmentectomy as it enables less tissue dissection
and allows me to maneuver more effectively within the patient’s
chest,” said PD Dr. Med. Volker Steger of the University of
Tubingen, Germany. “We appreciate Dextera’s support for this
international training course.”
“We believe these courses, where surgeons learn cutting-edge
surgical techniques for VATS procedures, are critically important
to demonstrate how the MicroCutter 5/80’s small size and wider
articulation help to enable adoption of less invasive surgical
approaches for these technically challenging procedures,” said Liam
Burns, vice president of worldwide sales and marketing for Dextera
Surgical.
MicroCutter Indication Information
In the United States, the MicroCutter 5/80 Stapler and
MicroCutter 30 White, Blue and Curved Tip White and Blue Reloads
are intended for transection and resection in multiple open or
minimally invasive urologic, thoracic, and pediatric surgical
procedures, as well as application for transection, resection,
and/or creation of anastomoses in the small and large intestine,
and the transection of the appendix. With the recent clearance, the
MicroCutter 5/80 Stapler and MicroCutter 30 White and Curved Tip
White Reloads may additionally be used in conjunction with open
solid organ parenchymal dissection techniques on veins four to five
millimeters in diameter and arteries three to seven millimeters in
diameter.
About Dextera Surgical
Dextera Surgical designs and manufactures proprietary
stapling devices for minimally invasive surgical procedures. In the
U.S., surgical staplers are routinely used in more than one million
minimally invasive laparoscopic, video-assisted or robotic-assisted
surgical procedures annually.
Dextera Surgical also markets the only automated
anastomosis devices for coronary artery bypass graft (CABG) surgery
on the market today: the C-Port® Distal Anastomosis Systems and
PAS-Port® Proximal Anastomosis System. These products, sold
by Dextera Surgical under the Cardica brand name, have
demonstrated long-term reliable clinical performance for more than
a decade.
Forward-Looking Statements
The statements in this press release regarding the beneficial
use of the MicroCutter 5/80 during segmentectomy procedures are
"forward-looking statements." There are a number of important
factors that could cause results to differ materially from those
indicated by these forward-looking statements, including the risks
detailed from time to time in Dextera Surgical’s reports filed with
the U.S. Securities and Exchange Commission, including its
Quarterly Report on Form 10-Q for the quarter ended March 31,
2017, under the caption “Risk Factors.” Dextera Surgical expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein. You are encouraged to read Dextera Surgical’s reports filed
with the U.S. Securities and Exchange Commission, available at
www.sec.gov.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170927005824/en/
Dextera Surgical Inc.Bob Newell, 650-331-7133Vice President,
Finance and Chief Financial
Officerinvestors@dexterasurgical.com